{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:19:00Z","timestamp":1781050740964,"version":"3.54.1"},"reference-count":37,"publisher":"Japanese Circulation Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2011]]},"DOI":"10.1253\/circj.cj-10-1084","type":"journal-article","created":{"date-parts":[[2011,4,12]],"date-time":"2011-04-12T05:20:45Z","timestamp":1302585645000},"page":"1334-1342","source":"Crossref","is-referenced-by-count":19,"title":["Clinical Outcome in Patients With Paroxysmal or Persistent Atrial Fibrillation Receiving Bepridil"],"prefix":"10.1253","volume":"75","author":[{"given":"Tsuyoshi","family":"Shiga","sequence":"first","affiliation":[{"name":"Department of Cardiology, Tokyo Women's Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Women's Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyoko","family":"Naganuma","sequence":"additional","affiliation":[{"name":"The Center for Clinical Research, Tokyo Women's Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Hosaka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Women's Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morio","family":"Shoda","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Women's Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Hagiwara","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Women's Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation: Analysis and implications. Arch Intern Med 1995; 155: 469-473.","DOI":"10.1001\/archinte.1995.00430050045005"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.18.2370"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Crijns HJGM, Van Den Berg MP, Van Gelder IC, Van Veldhuisen DJ. Management of atrial fibrillation in the setting of heart failure. Eur Heart J 1997; 18: C45-C49.","DOI":"10.1093\/eurheartj\/18.suppl_C.45"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Heart Study. Stroke 1991; 22: 983-988.","DOI":"10.1161\/01.STR.22.8.983"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998; 98: 946-952.","DOI":"10.1161\/01.CIR.98.10.946"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000072767.89944.6E"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00886-X"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq278"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Camm AJ. Safety considerations in the pharmacological management of atrial fibrillation. Int J Cardiol 2008; 127: 299-306.","DOI":"10.1016\/j.ijcard.2007.11.006"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators: A Comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.","DOI":"10.1056\/NEJMoa021328"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021375"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708789"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ogawa S, Yamashita T, Yamazaki T, Aizawa Y, Atarashi H, Inoue H, et al. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. Circ J 2009; 73: 242-248.","DOI":"10.1253\/circj.CJ-08-0608"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000121736.16643.11"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(92)90953-V"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(92)90961-W"},{"key":"17","unstructured":"17. Yasuda M, Nakazato Y, Yamashita H, Kawano Y, Iida Y, Nakazato K, et al. The clinical usefulness of oral bepridil in the treatment of atrial flutter and fibrillation refractory to class I antiarrhythmic drugs. Jpn J Electrocardiol 2003; 23: 53-60 (in Japanese)."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Otsuka T, Yamashita T, Sagara K, Iinuma H, Fu L. Efficacy and limitation of oral bepridil for atrial fibrillation refractory to class I antiarrhythmic drugs. Jpn J Electrocardiol 2004; 24: 428-433 (in Japanese).","DOI":"10.5105\/jse.24.428"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Fujiki A, Sakamoto T, Iwamoto J, Nishida K, Nagasawa H, Mizumaki K, et al. Pharmacological cardioversion of persistent atrial fibrillation with and without a history of drug-resistant paroxysmal atrial fibrillation. Circ J 2006; 70: 1138-1141.","DOI":"10.1253\/circj.70.1138"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1253\/circj.71.1250"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(03)00672-6"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Nakazato Y, Yasuda M, Sasaki A, Iida Y, Kawano Y, Nakazato K, et al. Conversion and maintenance of sinus rhythm by bepridil in patients with persistent atrial fibrillation. Circ J 2005; 69: 44-48.","DOI":"10.1253\/circj.69.44"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Imai S, Saito F, Takase H, Enomoto M, Aoyama H, Yamaji S, et al. Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm. Circ J 2008; 72: 709-715.","DOI":"10.1253\/circj.72.709"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-08-1061"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Yasuda M, Nakazato Y, Sasaki A, Kawano Y, Nakazato K, Tokano T, et al. Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter. Circ J 2006; 70: 662-666.","DOI":"10.1253\/circj.70.662"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(85)90799-4"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199244050-00009"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC\/AHA\/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-e354.","DOI":"10.1093\/eurheartj\/ehm315"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Braunwald E. Unstable angina: A classification. Circulation 1989; 80: 410-414.","DOI":"10.1161\/01.CIR.80.2.410"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.","DOI":"10.7326\/0003-4819-130-6-199903160-00002"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2004.09.053"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2008.08.011"},{"key":"33","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.644484"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(92)90962-X"},{"key":"35","doi-asserted-by":"publisher","DOI":"10.1172\/JCI25539"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Sugi K, Kusano A, Noro M, Numata A, Tezuka N, Nakae T, et al. Characteristics of pharmacokinetics of bepridil. Jpn J Electrocardiol 2007; 27: 30-35 (in Japanese).","DOI":"10.5105\/jse.27.30"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Kurita T, Yasauda M, Nakazato Y, Takahashi N, Yamashita T, Yasuda S, et al. Proarrhythmia of bepridil. Jpn J Electrocardiol 2007; 27: 61-73 (in Japanese).","DOI":"10.5105\/jse.27.61"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/circj\/75\/6\/75_CJ-10-1084\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T03:58:49Z","timestamp":1616644729000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/circj\/75\/6\/75_CJ-10-1084\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-10-1084","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}